About
Treatments for hormone-driven cancers
Areas of Focus
Categories
Small Molecule PharmaceuticalNJ, NY, PA
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
4
As Collaborator
4
Total Enrollment
213
By Phase
PHASE1: 3PHASE1/PHASE2: 2PHASE2: 3
By Status
RECRUITING: 2WITHDRAWN: 2TERMINATED: 2ACTIVE_NOT_RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06756035Lead Sponsor
CT-95 in Advanced Cancers Associated With Mesothelin Expression
PHASE1Recruiting
70 participants
Started: Mar 31, 2025 · Completed: Dec 31, 2028
NCT06515613Lead Sponsor
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
PHASE1Recruiting
80 participants
Started: Jul 10, 2024 · Completed: Mar 31, 2028
NCT06938711Lead Sponsor
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
PHASE1/PHASE2Withdrawn
Started: Jun 30, 2023 · Completed: Dec 31, 2023
NCT05618613Lead Sponsor
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
PHASE1/PHASE2Terminated
4 participants
Started: Dec 2, 2022 · Completed: Jun 23, 2023
NCT04738292Collaborator
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
PHASE2Terminated
11 participants
Started: Oct 5, 2021 · Completed: May 15, 2023
Locations (1)
Headquarters
Philadelphia, PA, United States
Map
Loading map...